Entrada Therapeutics (TRDA) Share-based Compensation (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Share-based Compensation of $4.7 million for Q1 2026, down 6.74% year-over-year from $5.1 million in Q1 2025, and up 8.86% quarter-over-quarter from $4.4 million in Q4 2025.
Entrada Therapeutics (TRDA) Share-based Compensation (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Share-based Compensation history runs 7 years deep, the most recent figure standing at $4.7 million for Q1 2026.
- In Q1 2026, Share-based Compensation fell 6.74% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $19.3 million (changed 0.02% YoY), while the FY2025 annual figure was $19.6 million, up 9.46% from the prior year.
- Share-based Compensation for Q1 2026 stood at $4.7 million, up from $4.4 million in the prior quarter.
- The five-year high for Share-based Compensation was $68.3 million in Q4 2023, with the low at -$7.0 million in Q4 2022.
- The 5-year median for Share-based Compensation is $4.6 million (2024), against an average of $7.1 million.
- Peak annual rise in Share-based Compensation reached 1113.32% in 2022, while the deepest fall reached 581.0% in 2022.
- Entrada Therapeutics' Share-based Compensation stood at -$7.0 million in 2022, then jumped by 1074.11% to $68.3 million in 2023, then slumped by 93.12% to $4.7 million in 2024, then slipped by 7.28% to $4.4 million in 2025, then climbed by 8.86% to $4.7 million in 2026.
- Business Quant data shows TRDA's Share-based Compensation at $4.7 million in Q1 2026, $4.4 million in Q4 2025, and $5.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - | 5.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.15 Mn |
| Jun 30, 2026 | 5.15 Mn |
| Mar 31, 2026 | 4.74 Mn |
| Mar 31, 2026 | 4.74 Mn |
| Dec 31, 2025 | 4.36 Mn |
| Dec 31, 2025 | 4.36 Mn |
| Sep 30, 2025 | 5.12 Mn |
| Sep 30, 2025 | 5.12 Mn |
| Jun 30, 2025 | 5.05 Mn |
| Jun 30, 2025 | 5.05 Mn |
| Mar 31, 2025 | 5.09 Mn |
| Mar 31, 2025 | 5.09 Mn |
| Dec 31, 2024 | 4.70 Mn |
| Dec 31, 2024 | 4.70 Mn |
| Sep 30, 2024 | 4.86 Mn |
| Sep 30, 2024 | 4.86 Mn |
| Jun 30, 2024 | 4.62 Mn |
| Jun 30, 2024 | 4.62 Mn |
| Mar 31, 2024 | 3.73 Mn |
| Mar 31, 2024 | 3.73 Mn |